Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report
Main Authors: | Luca Borghesi, Valentina Viaggi, Marco Franzetti, Matteo Montoli, Carola Mauri, Giovanni Moioli, Mauro Roberto Benvenuti, Stefania Piconi, Francesco Luzzaro |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | Journal of Global Antimicrobial Resistance |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716521002101 |
Similar Items
-
Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations
by: Wesley D. Kufel, et al.
Published: (2020-01-01) -
Pleural empyema
by: Crisanto Abad Celuria, et al.
Published: (2005-12-01) -
Pleural empyema
by: Crisanto Abad Celuria, et al.
Published: (2005-12-01) -
Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa
by: Caterina Ferretti, et al.
Published: (2024-06-01) -
New mutations in genes associated with cefiderocol resistance in a clinical isolate of Pseudomonas aeruginosa
by: Bocharova Yu.A., et al.
Published: (2023-12-01)